American College of Cardiology (ACC) Features Expert Analysis on the Importance of Addressing Anemia With Blood Volume Analys...
13 Julho 2021 - 9:30AM
Daxor Corporation (NYSE MKT: DXR), the global leader in blood
volume measurement technology, today announces an expert analysis
titled, “Anemia and Heart Failure: Guidance for Clinicians and
Trialists'' published July 6, 2021 in the American College of
Cardiology (ACC) online clinical topics section:
https://www.acc.org/latest-in-cardiology/articles/2021/07/06/12/18/anemia-and-heart-failure.
The authors focus on detecting and addressing anemia in heart
failure (HF) patients, a common and often unrecognized condition
causing increased length of hospitalization and worsening outcomes.
The document specifically states, “every attempt should be made to
measure and know total blood volume” and cites outcome studies that
identify total blood volume via Daxor's unique blood volume
analysis technology.
The analysis additionally emphasizes the
importance of direct measurement of a patient's red blood cell
volume, also citing supporting references of research papers and
clinical trials applying blood volume measurements using Daxor’s
BVA-100 Blood Volume Analyzer. The authors state that “...
connecting the current gaps in awareness of anemia prevalence in
heart failure patients, the impact of current anemia diagnostics,
and the potential for therapeutics to be more precisely targeted to
improve safety and outcomes, it becomes clearer to us that there is
some missing link—and it just may be how we think about what anemia
represents and the priority we place on its measurement,
management, and treatment.”
“Over 6 million Americans suffer from heart
failure, one of the most prevalent and deadly diseases leading to
nearly 1 million deaths and 1 million hospitalizations annually,
and addressing anemia effectively is an important part of the
solution,” said Michael Feldschuh, CEO and President of Daxor
Corporation. “Our proprietary BVA-100 blood test precisely
quantifies the intravascular blood, plasma and red cell volume
informing anemia and helps guide appropriate treatment strategies
-- resulting in significantly better clinical and economic benefits
for patients and hospitals.”
In addition to its current FDA-cleared BVA-100
blood test, Daxor is developing next-generation testing platforms
under multiple contract awards with the U.S. Department of Defense
and support from the National Institutes of Health, slated for
release in 2022.
About Daxor
Corporation
Daxor Corporation (NYSE: DXR) is the global
leader in blood volume measurement technology focused on blood
volume testing innovation (organized as an investment company with
fully-owned innovative medical instrumentation and biotechnology
operations). We developed and market the BVA-100® (Blood Volume
Analyzer), the first diagnostic blood test cleared by the FDA to
provide safe, accurate, objective quantification of blood volume
status and composition compared to patient-specific norms. The BVA
technology enhances hospital performance metrics in a broad range
of surgical and medical conditions, including heart failure and
critical care, by informing treatment strategies, resulting in
significantly improved multiple measures of patient outcomes.
Daxor's mission is to advance healthcare by enabling optimal fluid
management with blood volume analysis. Daxor’s vision is optimal
blood volume for all. For more information, please visit our
website at Daxor.com.
Forward-Looking Statements
Certain statements in this release may include
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, including without
limitation, statements regarding the impact of hiring sales staff
and expansion of our distribution channels. Forward-looking
statements are predictions, projections and other statements about
future events that are based on current expectations and
assumptions and, as a result, are subject to risks and
uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this
release, including, without limitation, those risk associated with
our post-market clinical data collection activities, benefits of
our products to patients, our expectations with respect to product
development and commercialization efforts, our ability to increase
market and physician acceptance of our products, potentially
competitive product offerings, intellectual property protection,
FDA regulatory actions, our ability to integrate acquired
businesses, our expectations regarding anticipated synergies with
and benefits from acquired businesses, and additional other risks
and uncertainties described in our filings with the SEC.
Forward-looking statements speak only as of the date when made.
Daxor does not assume any obligation to publicly update or revise
any forward-looking statements, whether as a result of new
information, future events or otherwise.
Investor Relations Contact:Bret
ShapiroSr. Managing Partner, CORE
IR516-222-2560brets@coreir.com
Daxor (AMEX:DXR)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Daxor (AMEX:DXR)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024